ArticleBMC biotechnology2025
Marine-derived Acremonium strain prioritization using untargeted metabolomics approach for the identification of cytotoxic cyclic depsipeptides.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ChemBioParis 2025: Approaching Biology Through Chemistry in the City of Light.Chembiochem : a European journal of chemical biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Arctic environment, characterized by extreme conditions, hosts a largely untapped reservoir of fungal communities that have adapted to these harsh conditions by producing specialized bioactive secondary metabolites. Among these, Acremonium species also remain underexplored, despite their potential to produce structurally diverse and biologically active secondary metabolites. This is largely due to difficulties in sampling in remote Arctic regions and limited research focus on fungi from such environments. This study aimed to use an integrated workflow combining metabolomics, chemometrics, and bioactivity screening to prioritize Acremonium strains for the identification of bioactive secondary metabolites. We applied this workflow to investigate six Acremonium strains associated with driftwood from the Arctic: A. ellipsoideum (F1, F2), A. synnematoferum (F3, F4, F5), and A. multiramosum (F6), aiming to identify cytotoxic secondary metabolites.
resultsThe integrated metabolomics and chemometrics approach revealed unique chemical fingerprints for A. ellipsoideum (F1) and A. synnematoferum (F5) among the six strains. By further combining bioactivity screening results, strain F5 was prioritized for further detailed study. Five compounds were isolated from F5 and structurally elucidated as cyclic depsipeptides: destruxin-A4 chlorohydrin (1), trichomide D (2), destruxin-A5 (3), homodestruxin (4), and homodestcardin (5). All compounds exhibited cytotoxic effects against the tested cell lines but did not exhibit activity in the targeted bioassays against the kinase FLT3 or the phosphatase PTP1B. Cytotoxic destruxin-type compounds likely play a significant ecological role, as they have been reported to exhibit entomopathogenic, nematocidal, and phytotoxic effects.
conclusionThe identification of five known cytotoxic destruxin-type depsipeptides from A. synnematoferum as a new source expands the chemical diversity known for this genus and underscores their potential for the development of cytotoxic agents. These findings highlight not only the value of Arctic fungi as a reservoir of bioactive compounds but also the necessity of deciphering the ecological roles of cytotoxic metabolites produced by these organisms as they adapt to extreme environments. Furthermore, this study highlights the effectiveness of multi-informative-driven strain prioritization in uncovering bioactive metabolites from new fungal sources, emphasizing the significance of exploring Arctic fungal diversity for its potential to enhance chemical diversity, contribute to drug development, and broaden our understanding of ecological roles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.